Capabilities of our Catapult partners
Learn more about the Capabilities of our Catapult partners.
- CPI
CPI accelerates the development, scale-up and commercialisation of deep tech and sustainable manufacturing solutions. Through our team of scientists, technologists and innovation experts and infrastructure, we look beyond the obvious to transform healthcare and drive towards a sustainable future. CPI has been delivering innovation across pharmaceutical processes for over a decade, connecting dots across the ecosystem to make inventions reality.
Whether your product is a small molecule or a biologic we have experts able to support across process design, development, optimisation and scale up to manufacturing. We have in depth experience across multiple modalities including monoclonal antibodies, peptides, virus like particles, RNA, live biotherapeutic products, oligonucleotides and more. By utilising our national centres; the National Biologics Manufacturing Centre (NBMC), Medicines Manufacturing Innovation Centre (MMIC) and Intracellular Drug Delivery Centre (IDDC), you can gain access to world class facilities ready to support you in any part of your medicines manufacturing journey. With a keen focus on ensuring your medicine will be suitable to scale and manufacture we aim to develop the most sustainable process suitable to align with the net zero targets of the NHS.
MDC is a national Life Sciences service that reshapes drug discovery for patient benefit by transforming the best of UK science into better treatments. We provide extensive experience in industrial medicines discovery combined with access to innovative technologies and platforms including:
- Translational Imaging – In-vivo biodistribution, pharmacokinetics, disease profiling and efficacy studies.
- Cellular Sciences - In-vitro physical characterisation and cellular assays, using complex cell models.
- Biomarkers – Ex-vivo, end point analysis of cell models, preclinical and clinical tissues using a range of advanced bioanalytical technologies, supporting biomarker strategies and beyond.
MDC work with innovators to understand their project’s needs and challenges. Using our expertise and industry-leading insight we develop and implement a bespoke project plan that will deliver the data needed to accelerate the process towards commercial success.
As an example: Medicines Discovery Catapult can leverage its RNA nanotherapeutic pipeline to screen an LNP library to identify efficacious formulations, which could then be subject to in-depth characterisation. This would involve, assaying 100 distinct LNPs encapsulating GFP mRNA for potency and toxicity in HeLa cells at three concentrations. Promising formulations could then be analysed in depth, including detailed physicochemical assessment, ED50 determination in cell lines and primary cells, and mechanistic assessment of cellular interaction an endosomal disruption. This would provide a structure-activity package to identify lead candidates that can be prioritised for additional preclinical study.
The CGTC brings deep expertise in navigating the interconnected supply chain of advanced therapies, where healthcare delivery, manufacturing quality control, and regulatory compliance are inseparable. The rise of personalised medicines, including autologous cell and gene therapies, is redefining how medicines are developed and scaled, creating challenges around cost, complexity, and compliance. CGTC is uniquely positioned to help SMEs meet these challenges through its integrated ecosystem: from CERSI-AT and the ATTC network driving clinical adoption and access strategies, to the Manufacturing Innovation Centre, Digital and Automation Testbed (DAT) labs, and Process Analytical Technology (PAT) labs advancing industrialisation and quality surveillance. Our expertise spans gene modification, viral vector manufacturing, and advanced cell processing, including semi-continuous and continuous manufacturing strategies, and the differentiation and expansion of cells in both 2D and 3D culture systems. By applying automated platforms and scale-enabling technologies, we help manufacturers de-risk critical steps, reduce cost of goods, and achieve reproducible, regulatory-aligned manufacturing at scale. For medicines manufacturers, this means tailored support to accelerate their innovations from laboratory to compliant, commercially viable manufacture, enabling delivery of next-generation therapies within a new paradigm of medicines manufacturing.